The Upcoming PCAC Meeting The FDA notice confirms that the PCAC will convene this summer to evaluate whether to recommend the following seven bulk drug substances for inclusion on the 503A bulks list: July 23, 2026: BPC-157 (free base / acetate) KPV (free base / acetate) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) (free base / acetate) MOTs-C (free base / acetate) July 24, 2026: Emideltide (DSIP) (free base / acetate) Semax (free base / acetate) Epitalon (free base / acetate) All seven substances are of considerable interest to compounding pharmacies, prescribers, and patients
These studies suggest that T4 is negatively correlated with endotoxemia and could suppress proinflammatory TLR signaling and reduce inflammatory cytokines
THANK YOU, THANK YOU, THANK YOU
This combination provides comprehensive support for skin health and brightness
Don't think it has
The UK shows a CAGR of 6.2% , fuelled by millennial preferences for antioxidants, while France records the lowest among these at 6.1% , driven by beauty-focused supplement consumption
)
